Home / Case Studies / Divestiture and licensing opportunities for a pre-clinical product
Divestiture and licensing opportunities for a pre-clinical product
Objective
Prioritizing indications to understand commercial opportunity of an existing pipeline product to create strategies and scenarios for divestiture or licensing opportunities
Approach
Evaluate Mechanism of Action and clinical trial feasibility of the pre-clinical product
Assess 25 indications for clinical evidence, trial feasibility, unmet need, KOL perspective and market potential
Analyze market opportunities for the top 10 indications using KOL insights
Forecast revenue and value for the top 4 indications
Outcome
Identified 25 indications based on strategy and clinical evidence
Ranked 25 indications through KOL interviews, selecting the top 10
Conducted qualitative interviews to assess product placement and TPP reaction, identifying the top 4 market opportunities
Forecasted revenue and valuation for the top 4 indications
Client Benefits
Helped the client to understand the commercial potential of the product across 25 indications
Our analysis enabled them to decide whether to prioritize clinical development or divest the product
Trial prioritization helped the client identify high-potential indications with unmet needs
